Evidence map›Paper›PMID 41870698›Full record

ArticleNeurochemical research2026

Ibogalogs Activate the 5-HT

Deborah Rudin, Xintong Ren, Matthias E Liechti, Niu Huang, Hugo R Arias

Abstract read
PubMed Publisher
In one paragraph

Article in Neurochemical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Deborah Rudin *Division of Clinical Pharmacology and Toxicology, Department of Biomedicine, University Hospital Basel, Basel, Switzerland.
Xintong Ren *College of Life Science, Beijing Normal University, Beijing, China.
Matthias E LiechtiDivision of Clinical Pharmacology and Toxicology, Department of Biomedicine, University Hospital Basel, Basel, Switzerland.
Niu HuangNational Institute of Biological Sciences, No. 7 Science Park Road, Zhongguancun Life Science Park, Beijing, China.
Hugo R AriasDepartment of Pharmacology and Physiology, College of Osteopathic Medicine, Oklahoma State University Center for Health Sciences, Tahlequah, OK, USA. hugo.arias@okstate.edu.

Funding

Office of Research, Oklahoma State University Center for Health Sciences N/A
6 · The paper itself

Abstract

The objective of this study is to determine the binding and functional activity of a variety of ibogalogs and their pyridoindole homologs at the serotonin subtype 2 A receptor (5-HT

Indexed as

IndolesReceptor, Serotonin, 5-HT2ASerotonin 5-HT2 Receptor AgonistsAnimalsHumansSerotonin 5-HT2 Receptor AntagonistsThiophenes1-(5-(2-thenyloxy)-1H-indol-3-yl)propan-2-amineIndolesReceptor, Serotonin, 5-HT2ASerotonin 5-HT2 Receptor AgonistsSerotonin 5-HT2 Receptor AntagonistsThiophenes5-HT2A and 5-HT2B receptorsIbogalogsMolecular modelingPyrido-indole

Identifiers

PMID41870698

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.